Inflammatory intestinal diseases · 2025
Emu Oil: A Potential Adjunct to Inflammatory Bowel Disease Treatment?
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mhlanga Sisanda Nomcebo, Howarth Gordon Stanley, Mashtoub Suzanne
Аннотация
BACKGROUND: Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is a chronic lifelong condition that affects the colon to a variable extent. Current treatments for IBD include aminosalicylate-based drugs, corticosteroids, antibiotics, immunomodulators, biologics, other small-molecule drugs, and surgical intervention. Nonetheless, treatment options are variably effective, associated with serious side effects, and often leave individuals at risk of relapse.
SUMMARY: In this narrative review, we explore emu oil (EO), a naturally sourced agent, that may be utilised to broaden therapeutic options in IBD. The anti-inflammatory, antioxidant, reparative, and protective properties of EO have been attributed to its unique blend of fatty acids and non-triglyceride fraction. To date, several preclinical trials of orally administered EO have demonstrated these properties in a range of intestinal inflammatory conditions, showing reduced inflammation and mucosal damage, together enhancing intestinal healing.
KEY MESSAGES: While EO remains an interesting candidate for future investigations, current knowledge is limited to animal models and its clinical relevance is yet to be defined. Well-designed clinical trials will be essential to determine the safety and efficacy of EO before it can be considered as a potential adjunct to conventional therapy for IBD.
SUMMARY: In this narrative review, we explore emu oil (EO), a naturally sourced agent, that may be utilised to broaden therapeutic options in IBD. The anti-inflammatory, antioxidant, reparative, and protective properties of EO have been attributed to its unique blend of fatty acids and non-triglyceride fraction. To date, several preclinical trials of orally administered EO have demonstrated these properties in a range of intestinal inflammatory conditions, showing reduced inflammation and mucosal damage, together enhancing intestinal healing.
KEY MESSAGES: While EO remains an interesting candidate for future investigations, current knowledge is limited to animal models and its clinical relevance is yet to be defined. Well-designed clinical trials will be essential to determine the safety and efficacy of EO before it can be considered as a potential adjunct to conventional therapy for IBD.